Galenica strengthens its logistics business

(PresseBox) ( Bern, )
On 5 January 2009, the Galenica Group will acquire the entire share capital of Switzerlandbased Globopharm AG and its subsidiaries. Globopharm specialises in pharma distribution and is active in various business areas: its core business encompasses logistics services for pharma companies (prewholesale). Globopharm also supplies specialists and patients with its own range of healthcare products and runs a pharmacy. Globopharm ideally complements and strengthens the Galenica Group's current operations in Switzerland. It will expand and strengthen the prewholesale business of its subsidiary Alloga in particular. In addition, the other business areas will complement the Logistics and Retail business sectors, thereby contributing to sustained growth.

Globopharm AG offers its customers various services in pharma logistics. Its core business encompasses logistics services for the pharma industry (prewholesale) by stocking and delivering products based upon orders by the pharmaceutical company's customers. Globopharm also has its own range of healthcare products and supplies them directly to pharmacists, doctors and to hospitals.

Globopharm was founded in 1947 as a family business and currently employs a staff of about 130. The company is based in Egg (ZH). Globopharm also operates two logistical centers in Stäfa (ZH) and Villmergen (AG) and runs a pharmacy in Zollikerberg (ZH). In 2007 Globopharm generated total sales of about CHF 77 million from which CHF 17 million stem from service related sales of the prewholesale business.

Strengthening the prewholesale business

The acquisition of Globopharm will strengthen Galenica's prewholesale business in particular and enable its subsidiary Alloga to sustainably expand its customer base and service volume based on its current infrastructure. Furthermore, Globopharm's other business areas will ideally complement the Galenica Group's activities in the Logistics and Retail business sectors and support the expansion and further development of their market positions.

Continuity and development

Following the structural change in the healthcare markets, especially the growing pressure on costs and margins, it is becoming increasingly difficult for smaller companies to achieve the necessary critical mass to position themselves successfully in the market over the long term. With the integration of Globopharm into the Galenica Group the needs and requirements of customers and market partners will continue to be met in the future.

Globopharm's four business areas will be gradually integrated into the Galenica structure. The prewholesale and delivery business will be combined with the companies Alloga and Galexis in the Logistics business sector and direct delivery will be merged with the speciality pharmacy MediService. The pharmacy will be integrated into the Retail business sector.

The details of the operational incorporation of Globopharm's activities into the Galenica Group will be defined in an integration project. The project will be launched after the Closing of the transaction in January 2009. The primary goal is to continue to safeguard the quality of services and to further develop the service offering. Planning for the integration is due for completion by the end of the first quarter 2009. At this time it shall be communicated to what extent work locations will be transferred and how this will affect jobs. If a location is moved the jobs affected will be integrated into the Galenica Group wherever possible.
Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an